A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Cobitolimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms CONDUCT
- Sponsors InDex Pharmaceuticals
- 29 Jun 2017 Last checked against European Clinical Trials Database record.
- 21 Jun 2017 According to an InDex Pharmaceuticals media release, the first patient has been enrolled in this trial. Professor Walter Reinisch is Medical Advisor in this study.
- 26 Apr 2017 Status changed from not yet recruiting to recruiting.